Weedstock Daily Intelligence Brief
From the Village Green
Curated from social media posts and threads
Published: Saturday, May 23, 2026 | 7:30 AM ET | Curated by Sheeba
GTBIF: Green Thumb Files DEA Registration Apps for Schedule III Compliance
Green Thumb Industries (GTBIF) proactively filed applications with the DEA to register state-licensed medical cannabis operations under the expedited pathway following historic rescheduling to Schedule III. CEO Ben Kovler called it a practical step toward a more normalized, regulated federal industry. Read Full Release
MARKET: Cannabis Sector Faces Heavy Friday Selloff: CURLF Down 13.35%
US cannabis stocks experienced broad-based selling on May 15, with 29 of 38 tracked tickers closing lower. Curaleaf (CURLF) dropped 13.35% to $3.41; Cresco Labs (CRLBF) fell 9.89%. MSOS ETF declined 8.88%. No company-specific catalysts reported; pressure appears sentiment-driven. Market Analysis
ANALYSIS: Green Thumb vs. Curaleaf: Which Wins More From DEA Rescheduling?
Motley Fool analysis compares GTBIF and CURLF post-rescheduling: Green Thumb enters from financial strength ($1.2B 2025 revenue, 31% EBITDA margins, GAAP profitable). Curaleaf offers higher leverage play with international exposure (35% YoY Germany growth). Full Comparison
CURLF: Beacon Securities Raises Curaleaf Target to C$5.50 | Maintains Buy
Beacon Securities analyst Russell Stanley raised price target on Curaleaf (CURLF) to C$5.50 from C$5.00 while maintaining Buy rating. Upgrade reflects confidence in company positioning amid Schedule III transition and international growth momentum. Cantech Letter
CRON: Wall Street Zen Raises Cronos Group to Buy | TD Securities Maintains Buy
Cronos Group (CRON) received dual analyst support: Wall Street Zen upgraded to Buy in mid-May, while TD Securities maintained Buy rating and raised price target. Momentum reflects sector optimism around Schedule III benefits and improved financial visibility. Full Story
TLRY: Wall Street Analyst Sees 75% Upside in Tilray Following Rescheduling
At least one Wall Street analyst projects 75% upside in Tilray Brands (TLRY), citing Schedule III rescheduling benefits and improved tax treatment under IRC 280E relief. Target reflects confidence in Tilray execution and potential profit expansion. Motley Fool Analysis
AAWH: Haywood Maintains Buy on Ascend Wellness | $1.00 Price Target Affirmed
Haywood analyst Neal Gilmer maintained Buy rating and $1.00 price target on Ascend Wellness Holdings (AAWH) amid broader sector volatility. Northeastern US operator remains a quality pick despite recent selloff. Cantech Coverage
CGC: Canopy Growth to Report FY2026 Results June 15 | New Medical Portfolio Launch
Canopy Growth (CGC) announced full-year 2026 earnings presentation scheduled for June 15, 2026. Company previously launched expanded medical cannabis portfolio via Spectrum Therapeutics with new softgel configurations and enhanced dosing options. Canopy News
EARNINGS: Curaleaf Q1 2026: $324M Revenue, $70M Net Income, 49% Gross Margins
Curaleaf Holdings reported Q1 2026 net revenue of $324 million, international revenue of $47M (+35% YoY), and net income of $70 million with 49% gross profit margin. Company completed buyout of regional operator, consolidating market position. SEC Filing
REGULATORY: DEA Schedule III Registration Process Now Open for Cultivators, Distributors, Labs
DEA announced expedited registration pathway coming soon for cultivators, manufacturers, distributors, and testing labs seeking Schedule III cannabis licenses. Move accelerates compliance path for tracked companies and ancillary operators. Cannabis Business Times
Disclaimer: This brief is compiled from publicly available social media posts and news sources. Market data as of Friday, May 22, 2026 for US-listed equities. Published Saturday, May 23, 2026 | 7:30 AM ET | Curated by Sheeba